• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Medroxyprogesterone Acetate
    3 Drugs classified under this active ingredient

    All the Active Ingredient Drugs

    full basket chart

    Progestogen. Medroxyprogesterone Acetate 150 mg/ml, 500 mg / 3.3 ml.
    VIALS: 500 mg (3.3 ml x 150 mg/ml).
    See lit.
    Breast cancer, endometrial carcinoma.
    STERILE AQUEOUS SOLN: 1 x 150 mg
    (dispos. syringe). 150 mg by deep I.M.
    inject. during first 5 days of cycle.
    Repeat at 12 wk. intervals. Postpartum:
    150 mg by deep I.M. inject
    within first 5 days if not breast feeding.
    Repeat aft. 12 wks. See lit.
    Contracept. where medically indicated
    and where other means are inapplicable.
    C/I: Vag. bleed., breast malign.,
    thrombophleb., liver dysfunct.,
    sensitivity to compon.

    Provera 5 mg
    full basket chart
    Provera 5 mg

    Progestogen. Medroxyprogesterone Acetate 5 mg.
    TABS.: 100, 24. Endometriosis: Oral MPA 10 mg three times per day for 90 consec. days, begin. on the 1ST d of the menstrual cycle.
    Menopaus. Vasomotor Sympt.: Oral MPA 10-20 mg/d given continuous.
    Diagn. of prim. and secon. Amenorrhea: Oral MPA 2.5-10 mg/d for 5-10 d.
    Tmt. of second. Amenorrhea: Oral MPA 2.5- 10 mg dly. for 5-10 days, for 3 consecut. cycles. In pts. with hypotrophy of the endometrium, estrogens should be used concomit. with MPA ther.
    Dysfunctional (Anovulatory) Uterine Bleed.: Oral MPA 2.5 to 10 mg/ d for 5–10 d for 2-3 cycles and then discont. to see if the dysfunct. has regressed. If bleed. occurs from a poorly proliferative endometrium, estrogens should be used concomit. with MPA ther.
    Opposition of endometrial effects of estrogen in menopaus. women being treated with estrogen (Hormone Therapy [HT]): For women taking 0.625 mg of conjugated estrogen or an equivalent dly. dose of another estrogen, MPA can be given in one of two regimens:
    Continuous regimen of MPA- Oral MPA 2.5 to 5.0 mg dly.
    Sequent. regimen of MPA- Oral MPA 5 to 10 mg dly. for 10- 14 consecut. d. of a 28-d or monthly cycle.
    Indicated for cases requiring progesterone supplem.
    C/I: Hypersens. Known/suspect. preg. Known, past or suspect. breast cancer; Previous idiopathic or current venous thromboembolism (DVT, PE). Active/recent arterial thromboembolic dis. (e.g angina, MI); Acute liver dis., or a history of liver dis. as long as liver funct. tests have failed to return to normal. Porphyria.

    not in the basket chart

    Progestogen. Medroxyprogesterone Acetate 104 mg / 0.65 ml.
    PREFILL. SYRINGE: 1 x 104 mg (DmPA) in
    0.65 ml susp. for S.C. inject. 1st inject.
    during one of first 5 days of norm.
    menstr. cycle if not breastfeed. Repeat
    at 13 wk intervals. See lit.
    Long term female contracept. agent suit.
    for use in women of child bearing potent.
    Should only be used aft. other methods of
    contracept. discussed with pt. are
    C/I: Hypersens. to MPA. Known or
    suspect. pregn., known or suspect.
    malign. of breast or genital organs,
    undiagn. vag. bleed., severe hepat.
    impair, metabol. bone dis., active
    thromboembol. dis., current or past
    history. cerebrovasc. dis.